The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The study will run across 18 sites and enroll roughly 200 patients over 24 months
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Applications include detailed scientific rationale and supporting clinical evidence
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Subscribe To Our Newsletter & Stay Updated
